Johnson & Johnson Announces Reduced Cost Of TB Drug Bedaquiline For More Than 135 Countries Through Stop TB Partnership’s Global Drug Facility

Reuters: Johnson & Johnson cuts price of TB drug bedaquiline in poorer countries
“Johnson & Johnson said on Monday it was slashing the price of its version of tuberculosis drug bedaquiline to $340 from $400, for a six-month treatment, in low- and middle-income countries, to scale up its use during the COVID-19 pandemic. J&J’s bedaquiline, marketed under the brand name Sirturo, will be available at the reduced price to more than 135 eligible countries, through the United Nations-hosted Stop TB Partnership’s Global Drug Facility, created in 2001 to negotiate lower prices for treatments…” (Maddipatla, 7/6).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.